Peptides

Peptide Tracker

Loading peptide data...

Pharmacokinetic Data

Retatrutidesingle · t½ ~6 days

Long-acting GLP-1/GIP/GCGR tri-agonist. Weekly dosing; doses stack.

Phase 2 NEJM trial (Jastreboff 2023) reports half-life of ~6 days. Consistent across multiple sources. Weekly dosing means significant accumulation (~48% remaining at trough). Tmax ~36h from Phase 1 PK data.

Source 1Source 2
CPC 1295 / Ipamorelin Blendblend · t½ CJC-1295 (no DAC): ~30 min, Ipamorelin: ~2 hours

GH secretagogue blend. Both constituents clear within hours.

CJC-1295 without DAC (mod GRF 1-29) has a short half-life of ~30 minutes (Teichman 2006). Ipamorelin half-life ~2 hours based on Raun 1998 pharmacokinetic data. Both are GH secretagogues with rapid clearance.

Source 1Source 2
Glowblend · t½ GHK-Cu: ~1 hour, BPC-157: ~30 min, TB-500: ~2.5 hours

Recovery/skin blend. GHK-Cu (50mg), BPC-157 (10mg), TB-500 (10mg) in a 70mg vial. Daily subcutaneous dosing.

GHK-Cu plasma half-life ~0.5-2h across sources (PMC reviews); 1h chosen as midpoint for SC injection. BPC-157 t½ = 15.2 min IV in rats (Frontiers in Pharmacology 2022); adjusted to 30 min for SC due to absorption-limited (flip-flop) kinetics. Bioavailability ~14-19% in rats per same study. TB-500: original 11h estimate was equine metabolite detection window, not parent compound PK. Human IV Tβ4 phase 1 data shows t½ ~0.95-2.1h (dose-dependent); adjusted to 2.5h for SC depot effect. No human SC PK studies exist for any constituent. Ratios based on vial composition: 50/70, 10/70, 10/70.

Source 1Source 2Source 3

Data source: peptide-pharmacokinetics.json

To add a new peptide, run /research-peptide-pharmacokinetics PeptideName in Claude Code.